At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 20 target
Drug / intervention
AlloExbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05152368Phase 1RecruitingMonitorUpdated 14mo ago · Completion was 5mo agoSlow Enrollment
Long Recruiting
Monitor
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells Exosomes for the Treatment of Trigeminal Neuralgia
The Foundation for Orthopaedics and Regenerative Medicine·interventional·Posted Dec 9, 2021·Updated Apr 17, 2025
In Brief
A Phase 1 clinical trial evaluating AlloEx for Peripheral Neuropathy and Trigeminal Neuralgia. Currently recruiting, targeting 20 participants across 1 site.
Signals
Enrolling slower than its timeline implies
Detailed Summary
This trial will study the safety and efficacy of instillation of cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes for the treatment of Trigeminal Neuralgia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Neuropathy, Trigeminal Neuralgia
CountriesAntigua and Barbuda
Collaborators--
Timeline
Phase 1RecruitingOverdue
20222023202420252026
First PostedDec 2021
Enrollment StartSep 2022
Primary CompletionJan 2026
TodayJul 2026
First PostedDec 9, 2021
Enrollment StartSep 9, 2022
Primary CompletionJan 1, 2026
TodayJul 1, 2026
Enrollment to primary: 3.3 yearsPosted 4.6 years ago
Interventions
AlloExbiological
cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes